#USA #San Diego #Mondego Bio #ChemDiv #PTPN2

ChemDiv and Mondego Bio Extend Discovery Partnership in Immuno-Oncology

ChemDiv, a prominent player in drug discovery, has announced a significant extension of its partnership with Mondego Bio. This collaboration aims to further develop cutting-edge immuno-oncology therapies focusing on the PTPN2 protein, which is critical in cancer biology. The partnership comes on the heels of Mondego Bio's successful Series A financing, led by Biovance Capital, with additional support from OrbiMed Advisors and Torrey Pines Investment. This financial backing underscores the growing momentum behind Mondego's innovative strategies in the oncology field.

History of Collaboration

The collaboration between ChemDiv and Mondego Bio traces back to ChemDiv’s previous efforts in supporting the accelerated discovery of a drug candidate for Eilean Therapeutics LLC in the U.S. This initial venture laid the groundwork for the establishment of Mondego Bio in Portugal in 2025. The goal has always been to leverage advanced rational drug design techniques across various categories of inhibitors—reversible, covalent, and allosteric. Notably, these efforts have created a differentiated selectivity profile critical for achieving high oral bioavailability and robust efficacy in vivo while ensuring strong safety and tolerability—backbones of potentially best-in-class oncology therapeutics.

Ongoing Developments

The partnership will continue to evolve as ChemDiv advances its medicinal chemistry and discovery biology services. Upcoming initiatives will involve:

• - Supporting further backup series in medicinal chemistry.
• - Using Comprehensible Manufacturing and Chemistry (CMC) research to scale production of the main candidate for both non-GLP and GLP animal studies.
• - Employing computational methods alongside wet-lab pharmacology to expedite the transition to clinical trials.

This initiative will build on ChemDiv's extensive experience in designing selective kinase and phosphatase inhibitors, supported by its vast libraries of chemical compounds. Notably, ChemDiv utilizes AI and machine learning in its rational drug design processes, leading to enhanced optimization of drug leads while considering Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME/Tox).

Looking Ahead

Ilya Baimetov, COO of ChemDiv, emphasized the urgency of transitioning PTPN2 biology into actionable therapies. "By integrating our sophisticated rational design methodologies and robust medicinal chemistry capabilities with Mondego's pioneering immuno-oncology foundation, we are propelling the development of next-generation phosphatase inhibitors, which have the potential to set new standards in cancer treatment," he stated.

About Mondego Bio

Mondego Bio is situated in Portugal's Biocant biotech park and is focused on innovating best-in-class PTPN2 inhibitors. As part of its ongoing initiatives, the company plans to build on its recent financing success, driving forward its next-generation immuno-oncology strategy.

About ChemDiv

ChemDiv offers a comprehensive suite of services as an integrated discovery partner, ranging from target identification to clinical support. With a library of over 12 million compounds and a wealth of pre-designed chemical tool libraries, ChemDiv is equipped with the expertise necessary for custom medicinal chemistry and comprehensive drug discovery methodologies. Their commitment to innovation in drug design places them at the forefront of the biotechnology sector, making significant contributions toward breakthroughs in therapeutic solutions.

As the partnership continues to mature, the roles of ChemDiv and Mondego Bio promise to bring forth noteworthy advancements in immuno-oncology, highlighting their commitment to improving cancer therapies worldwide.